UCSF Pediatric Diabetes Program Director Steve Gitelman, MD has partnered with the Immune Tolerance Network (ITN) to launch a study involving ATG , or anti-thymocyte globulin, to see if this drug can halt the progression of new onset type 1 diabetes. The START trial (Study of Thymoglobulin to Arrest Type 1 Diabetes) hopes to recruit 66 volunteers, 18 – 35 years of age, within six weeks of diagnosis.
Two common cancer drugs have been shown to both prevent and reverse type 1 diabetes in a mouse model of the disease, according to research conducted at the University of California, San Francisco. The drugs – imatinib (marketed as Gleevec) and sunitinib (marketed as Sutent) – were found to put type 1 diabetes into remission in 80 percent of the test mice and work permanently in 80 percent of those that go into remission.
In recent breakthroughs, researchers have developed a process for reprogramming fully grown adult cells back into something akin to embryonic stem cells, called induced pluripotent stem cells, or iPS cells.
On Friday, November 13, a California Superior Court Judge ruled against a provision of an agreement between the American Diabetes Association (ADA) and the California Department of Education that would ensure students are provided appropriate care in the classroom.
The immune system is a powerful defensive weapon the body uses to identify and destroy invading organisms like bacteria and viruses. The cells of the immune system constantly patrol the body looking for such invaders. However, this defensive system must be carefully educated to distinguish between foreign material and the body’s own tissues, in order to prevent the immune system from mistakenly attacking its own body.
A new educational resource for diabetes is now available on the Internet, thanks to the UCSF Diabetes Teaching Center (DTC). Since it was launched in July 2008, thousands of families have visited the site. DTC Medical Director Martha Nolte Kennedy, MD and her staff are pleased that this website is providing diabetes education and self-management skills to the growing numbers worldwide who have limited access to diabetes specialists.
Last month, Doug Hanahan, PhD was elected to the prestigious Institute of Medicine (IOM), an organization that serves as adviser to the nation to improve health. Established in 1970 under the charter of the National Academy of Sciences, the IOM provides independent, objective, evidence-based advice to policymakers, health professionals, the private sector, and the public. Dr. Hanahan is a member of both the UCSF Diabetes Center and the Helen Diller Family Comprehensive Cancer Center.
Jeff Bluestone PhD, Mike German MD, and Matthias Hebrok PhD were recently awarded a three year JDRF Network Grant to explore Human Embryonic Stem Cell Source for Beta Cell Replacement.
Each year, the Haile T. Debas Academy of Medical Educators recognizes outstanding teachers at UCSF. These peer-nominated awards are intended to highlight outstanding front-line teachers of medical students and residents -- who might otherwise go unrecognized. We congratulate Mark Anderson, MD, PhD who was presented a 2008 Excellence in Teaching Award.
Hélène Bour-Jordan, Ph.D. and Mark S. Anderson, M.D., Ph.D.—researchers at the University of California-San Francisco (UCSF) Diabetes Center—were recently awarded a scientific research grant by The Neuropathy Association, a national patient-based non-profit organization headquartered in New York City.
A complete online diabetes education program, www.deo.ucsf.edu, has been launched by the University of California, San Francisco (UCSF) Diabetes Teaching Center. This website mirrors the highly successful American Diabetes Association (ADA) accredited teaching program curriculum created by UCSF clinicians and presented to thousands of patients at UCSF over the past 30 years.
Dr. Jeffrey A. Bluestone, University of California in San Francisco and Dr. Mark E. Cooper, Baker IDI Heart and Diabetes Institute in Melbourne, Australia, to Receive Honors & Additional Research Funding.
Beginning this year, the California Institute of Regenerative Medicine (CIRM) plans to support multi-year Disease Team Grants. To encourage planning for these awards, CIRM has created Disease Team Planning Awards that will enable a Principal Investigator to recruit a team and enlist its members to develop the content, management and administration of the proposed disease team.